Alcon to acquire Ivantis for $475m.

Alcon, a company provides eye care, agreed to acquire Ivantis, a minimally invasive glaucoma surgical solutions developer, for $475m. “Glaucoma is the second-largest cause of blindness after cataracts, impacting more than 75 million people globally, with significant unmet patient need. This transaction will allow us to add a uniquely effective product into our glaucoma portfolio around the world. Our global commercial footprint and development capabilities make us well positioned to build on the success of Ivantis and help even more patients see brilliantly with Hydrus Microstent," David Endicott, Alcon CEO.